Koninklijke Philips N.V.
PHGHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Koninklijke Philips N.V. focuses on Medical Devices services and products. Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The $25.12B market capitalization puts PHG squarely in large-cap range for its industry. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments.
Market Cap
$25.12B
Beta
0.92
P/E (TTM)
22.75
P/E (Fwd)
12.92
EPS (TTM)
$1.16
EPS (Fwd)
$2.04
ROE
8.4%
ROA
3.5%
Cash
$2.59B
Total Debt
$8.10B
Free CF
$1.52B
52W Change
15.7%
Annual Financials
Cash vs Debt
Koninklijke Philips N.V. carries $8.10B in total debt against $2.59B in cash reserves — debt is roughly 3.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $1.52B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 8.4%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $17.16B (2021) to $17.83B (2025).
As with any equity investment, PHG carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Koninklijke Philips N.V. and its sector.